In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In other words, the price has increased by $0.00 from its previous closing price. On the day, 2.83 million shares were traded. FATE stock price reached its highest trading level at $1.115 during the session, while it also had its lowest trading level at $1.03.
Ratios:
We take a closer look at FATE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.87 and its Current Ratio is at 7.87. In the meantime, Its Debt-to-Equity ratio is 0.34 whereas as Long-Term Debt/Eq ratio is at 0.32.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 04 ’25 when TAHL CINDY sold 9,037 shares for $1.06 per share. The transaction valued at 9,573 led to the insider holds 397,670 shares of the business.
Valamehr Bahram sold 14,466 shares of FATE for $15,396 on Aug 04 ’25. The President and CEO now owns 334,898 shares after completing the transaction at $1.06 per share. On Aug 04 ’25, another insider, TAHL CINDY, who serves as the Officer of the company, bought 9,037 shares for $1.06 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FATE now has a Market Capitalization of 121119896 and an Enterprise Value of -15055097. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.96 while its Price-to-Book (P/B) ratio in mrq is 0.52. Its current Enterprise Value per Revenue stands at -2.109 whereas that against EBITDA is 0.104.
Stock Price History:
The Beta on a monthly basis for FATE is 2.22, which has changed by -0.3674699 over the last 52 weeks, in comparison to a change of 0.14402747 over the same period for the S&P500. Over the past 52 weeks, FATE has reached a high of $1.99, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is -12.86%, while the 200-Day Moving Average is calculated to be -7.31%.
Shares Statistics:
According to the various share statistics, FATE traded on average about 2.11M shares per day over the past 3-months and 1463970 shares per day over the past 10 days. A total of 115.34M shares are outstanding, with a floating share count of 109.69M. Insiders hold about 4.91% of the company’s shares, while institutions hold 71.34% stake in the company. Shares short for FATE as of 1764288000 were 8184722 with a Short Ratio of 3.88, compared to 1761868800 on 6831984. Therefore, it implies a Short% of Shares Outstanding of 8184722 and a Short% of Float of 8.09.
Earnings Estimates
Currently, 9.0 analysts are dedicated to thoroughly evaluating and rating the performance of Fate Therapeutics Inc (FATE) in the stock market.The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.26 and low estimates of -$0.32.
Analysts are recommending an EPS of between -$1.1 and -$1.18 for the fiscal current year, implying an average EPS of -$1.15. EPS for the following year is -$1.16, with 9.0 analysts recommending between -$0.91 and -$1.37.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for FATE’s current fiscal year. The highest revenue estimate was $7.8M, while the lowest revenue estimate was $5.28M, resulting in an average revenue estimate of $6.36M. In the same quarter a year ago, actual revenue was $13.63M
